Israel - English - Ministry of Health

truemed ltd. - estradiol as hemihydrate; nomegestrol acetate - film coated tablets - nomegestrol acetate 2.5 mg; estradiol as hemihydrate 1.5 mg - estradiol - oral contraception

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - estradiol hemihydrate 1.55mg equivalent to estradiol 1.5 mg;  ; nomegestrol acetate 2.5mg;  ;   - tablet - 2.5mg/1.5mg - active: estradiol hemihydrate 1.55mg equivalent to estradiol 1.5 mg   nomegestrol acetate 2.5mg     excipient: colloidal silicon dioxide crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose opadry white 85f18422 purified talc colloidal silicon dioxide crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose opadry yellow 85f32865 purified talc - oral contraception

Australia - English - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - nomegestrol acetate, quantity: 2.5 mg; estradiol hemihydrate, quantity: 1.55 mg (equivalent: estradiol, qty 1.5 mg) - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; microcrystalline cellulose; purified talc; lactose monohydrate; colloidal anhydrous silica; titanium dioxide; iron oxide yellow; polyvinyl alcohol; macrogol 3350; iron oxide black - oral contraception.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

stragen nordic a.s. - nomegestrol acetate 5 mg - tablet - 5 mg - nomegestrol acetate 5 mg - nomegestrol

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: lactose; magnesium stearate; povidone; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - this medicine is indicated for use as: ? an oral contraceptive. ? treatment of moderate acne vulgaris in women who seek oral contraception. ? treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of drospirenone 3 mg /ethinylestradiol 20 ?g for pmdd was not assessed beyond 3 cycles. drospirenone 3 mg /ethinylestradiol 20 ?g has not been evaluated for treatment of pms (premenstrual syndrome), see section 5.1 pharmacodynamic properties - clinical trials.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ethinylestradiol,levonorgestrel -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ethinylestradiol,levonorgestrel -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ethinylestradiol,levonorgestrel -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ethinylestradiol, quantity: 30 microgram; levonorgestrel, quantity: 150 microgram - tablet, film coated - excipient ingredients: povidone; magnesium stearate; lactose; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - oral contraception.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - levonorgestrel, quantity: 100 microgram; ethinylestradiol, quantity: 20 microgram - tablet, film coated - excipient ingredients: maize starch; gelatin; magnesium stearate; hypromellose; macrogol 4000; titanium dioxide; iron oxide red; lactose monohydrate - oral contraception